# Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

> **NCT04526704** · PHASE4 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 32 (actual)

## Conditions studied

- Tenosynovial Giant Cell Tumor

## Interventions

- **DRUG:** Pexidartinib

## Key facts

- **NCT ID:** NCT04526704
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-20
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-07-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526704, "Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04526704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*